A Phase I trial showed that monthly injection of Amgen's investigational drug AMG 145 reduces bad cholesterol by as much as an additional 66% in patients already taking low to moderate doses of statins. AMG145 works by inhibiting the PCSK9 protein. A similar drug, REGN 727, is being developed by Regeneron Pharmaceuticals.

Full Story:

Related Summaries